The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment.

HIV protease inhibitors (PIs) show antimalarial activity in vitro and in animals. Whether this translates into a clinical benefit in HIV-infected patients residing in malaria-endemic regions is unknown. We studied the incidence of malaria, as defined by blood smear positivity or a positive Plasmodiu...

Full description

Bibliographic Details
Published in:	PLoS ONE
Main Authors:	Tina S Skinner-Adams, Alice S Butterworth, Kimberly A Porter, Ronald D'Amico, Fred Sawe, Doug Shaffer, Abraham Siika, Mina C Hosseinipour, Elizabeth Stringer, Judith S Currier, Tsungai Chipato, Robert Salata, Shahin Lockman, Joseph J Eron, Steven R Meshnick, James S McCarthy
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2012-01-01
Online Access:	http://europepmc.org/articles/PMC3317955?pdf=render

Similar Items

Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria
by: Sikiru Olatunji Usman, et al.
Published: (2020-11-01)

Recurrent oedema associated with the co-formulation of lopinavir and ritonavir Edema recorrente associado à co-formulação de lopinavir e ritonavir
by: Jorge Francisco C. Pinto, et al.
Published: (2004-08-01)

Toxicity for warfarine switching from lopinavir/ritonavir to dolutegravir
by: Ana Pelufo-Pellicer, et al.
Published: (2017-03-01)

The effect of lopinavir - ritonavir on mortality in COVID-19 pneumonia
by: Muhammed Emin Demirkol, et al.
Published: (2024-10-01)

COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi
by: Esma Eroğlu, et al.
Published: (2020-12-01)

The efficacy of nelfinavir and lopinavir/ritonavir in the treatment of HIV-infected pediatric patients
by: V. B. Denisenko,, et al.
Published: (2018-12-01)

Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
by: Adewale Bayode Owa, et al.
Published: (2020-10-01)

HPTLC Method for Simultaneous Determination of Lopinavir and Ritonavir in Capsule Dosage Form
by: A. V. Sulebhavikar, et al.
Published: (2008-01-01)

Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis
by: Bahman Amani, et al.
Published: (2021-05-01)

Correction: Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir).
by: Kathleen M. S. E. Reyskens, et al.
Published: (2013-01-01)

Hypertriglyceridaemia and the risk of pancreatitis six months post lopinavir/ritonavir initiation
by: Wilhelm P. Greffrath, et al.
Published: (2018-06-01)

Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children
by: Beatriz Larru Martinez, et al.
Published: (2010-03-01)

Electrospun Amorphous Solid Dispersions with Lopinavir and Ritonavir for Improved Solubility and Dissolution Rate
by: Ewelina Łyszczarz, et al.
Published: (2024-09-01)

USE OF LOPINAVIR/RITONAVIR ASSOCIATED WITH ERGOTAMINE RESULTING IN FOOT AMPUTATION: BRIEF COMMUNICATION
by: Fernando Raphael de Almeida Ferry, et al.
Published: (2014-06-01)

Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment
by: Paola Magro, et al.
Published: (2021-03-01)

Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities
by: Mario Ferreira Peixoto, et al.

Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities
by: Mario Ferreira Peixoto, M.D., et al.
Published: (2011-05-01)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
by: Nicola Gianotti, et al.
Published: (2017-01-01)

The Palatability of Lopinavir and Ritonavir Delivered by an Innovative Freeze-Dried Fast-Dissolving Tablet Formulation
by: David W. Pittman, et al.
Published: (2018-01-01)

Acute Kidney Injury Associated With Lopinavir/Ritonavir Combined Therapy in Patients With COVID-19
by: Yannick Binois, et al.
Published: (2020-10-01)

Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.
by: Richard A Murphy, et al.
Published: (2012-01-01)

Simultaneous determination of plasma lopinavir and ritonavir by chemometrics-assisted spectrophotometry and comparison with HPLC method
by: Chutima Matayatsuk Phechkrajang
Published: (2013-06-01)

Dyslipidaemia associated with the highly active antiretroviral therapy in aids patient: reversion after switching (stavudine to tenofovir and lopinavir/ritonavir to atazanavir/ritonavir)
by: Hamilton Domingos, et al.

The Effectiveness of Hydroxychloroquine Versus Hydroxychloroquine Plus Lopinavir/Ritonavir Therapy in SARSCoV- 2 Pneumonia
by: Ayşe BATIREL, et al.
Published: (2021-12-01)

Potentially fatal severe brady arrythmias related to Lopinavir-Ritonavir in a COVID 19 patient
by: Venkatesan Shree, et al.
Published: (2021-02-01)

Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis
by: Saad Alhumaid, et al.
Published: (2020-11-01)

Development of In Situ Self-Assembly Nanoparticles to Encapsulate Lopinavir and Ritonavir for Long-Acting Subcutaneous Injection
by: Irin Tanaudommongkon, et al.
Published: (2021-06-01)

Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial
by: Alexander M. Kaizer, et al.
Published: (2023-03-01)

A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections
by: Purwati, et al.
Published: (2021-01-01)

Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol
by: Yan-Ming Zeng, et al.
Published: (2020-05-01)

Comparative efficacy of repurposed drugs lopinavir-ritonavir and darunavir-ritonavir in hospitalised COVID-19 patients: insights from a tertiary centre cohort
by: Dóra Paróczai, et al.
Published: (2025-01-01)

Influence of traditional Chinese medicines on the in vivo metabolism of lopinavir/ritonavir based on UHPLC-MS/MS analysis
by: Linlin Li, et al.
Published: (2022-04-01)

Severe COVID-19 infection in a kidney transplant recipient treated with lopinavir/ritonavir, hydroxychloroquine and dexamethasone
by: Satriyo Dwi Suryantoro, et al.
Published: (2021-09-01)

Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.
by: Nguyen Thi Ngoc Lan, et al.
Published: (2014-01-01)

Bilateral pedal edema in an HIV patient: Lopinavir/Ritonavir-containing treatment regimen as a potential cause?
by: Hasan M. Shihab, et al.
Published: (2009-06-01)

What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed?
by: Yu. Yu. Kiselev, et al.
Published: (2020-10-01)

Antiretroviral Therapy with Ritonavir-Boosted Atazanavir- and Lopinavir-Containing Regimens Correlates with Diminished HIV-1 Neutralization
by: Eloisa Yuste, et al.
Published: (2024-10-01)

Comparable Efficacy of Lopinavir/Ritonavir and Remdesivir in Reducing Viral Load and Shedding Duration in Patients with COVID-19
by: Choon-Mee Kim, et al.
Published: (2024-08-01)

Clinical Profiles and Il-6 Level Analysis of Critical Covid-19 Patients Receiving Lopinavir-Ritonavir
by: Erwin Astha Triyono, et al.
Published: (2023-06-01)

Ritonavir and Lopinavir Suppress RCE1 and CAAX Rab Proteins Sensitizing the Liver to Organelle Stress and Injury
by: Atousa Khalatbari, et al.
Published: (2020-06-01)